Marea Therapeutics doses first patient in MAR002 phase 2 trial
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J. - Marea Therapeutics, a Lisata Therapeutics subsidiary, has administered the inaugural patient in its Phase 2 clinical trial for MAR002, a treatment for acromegaly. MAR002 is an allosteric monoclonal antibody targeting the growth hormone receptor. Acromegaly is a rare endocrine disorder caused by excessive growth hormone, often due to a pituitary adenoma, leading to elevated insulin-like growth factor-1.
The Phase 2 trial will enroll about 72 patients across three dose levels, following an initial 900 mg loading dose, against a placebo control. The main objective measures IGF-1 reduction after 10 weeks. Participants who complete the treatment may join an open-label extension. Investors can monitor Lisata Therapeutics' financial health and Fair Value analysis on InvestingPro, which tracks clinical milestones' impact on the company's valuation.
A Phase 1 study, presented at the 2026 Endocrine Society Annual Meeting, showed IGF-1 suppression and a dosing frequency that could be as infrequent as once every two weeks, compared to the current daily subcutaneous injections standard. Acromegaly impacts around 30,000 people in the U.S., causing abnormal enlargement of hands, feet, and facial features, and increasing the risk of organ damage, systemic complications, and shortened lifespan.
The average time from symptom onset to diagnosis is about eight years. Marea Therapeutics is a clinical-stage biotech firm developing medicines for cardioendocrine diseases, including MAR001 in Phase 2b trials for severe hypertriglyceridemia treatment.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.